|
|
Line 7,393: |
Line 7,393: |
| "title" : "A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy", | | "title" : "A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy", |
| "pmid" : "23877348" | | "pmid" : "23877348" |
| },
| |
| {
| |
| "timestamp" : "2022-03-10T21:09:46Z",
| |
| "briefDesignDescription" : "Rituximab in ANCA-Renal Vasculitis",
| |
| "fulltexturl" : "https://www.nejm.org/doi/full/10.1056/nejmoa0909169",
| |
| "pageid" : 4459,
| |
| "pdfurl" : "https://www.nejm.org/doi/pdf/10.1056/NEJMoa0909169",
| |
| "trainingLevel" : "fellow",
| |
| "citation" : "Jones RB, <i>et al</i>. \"Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis\". <i>The New England Journal of Medicine</i>. 2010. 363(3):211-232.",
| |
| "subspecialties" : "Rheumatology;Nephrology",
| |
| "expansion" : "",
| |
| "statusUsableDate" : "2022-03-10",
| |
| "briefResultsDescription" : "Rituximab not superior to cyclophosphamide",
| |
| "published" : "2010-07-15",
| |
| "pageName" : "RITUXVAS",
| |
| "diseases" : "Vasculitis;ANCA-Associated Vasculitis;Renal Vasculitis",
| |
| "abbreviation" : "RITUXVAS",
| |
| "title" : "Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitis",
| |
| "pmid" : "20647198"
| |
| }, | | }, |
| { | | { |